2013-12-20 13:29:51 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to ImmuCell Corporation (ICCC) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering ImmuCell Corporation (ICCC). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential ImmuCell Corporation investor.
Report Summary: ImmuCell Corporation is an average quality company with a positive outlook. ImmuCell Corporation has medium business growth and is run by passable management. The trend in ImmuCell Corporation fair value exchange rate against its closest rated-competitor, GenVec Inc, has been depreciating over the past 2 weeks. When compared to its closest competitor, ImmuCell Corporation shows similar overvaluation and is equally likely to outperform the market.
The report breaks down the Total StockMark into its three components - business, management and price, performing
an in-depth analysis of ImmuCell Corporation for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext and from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, One source West Services, and Dow Jones/Factiva.
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering 31 different markets and over 22,000 companies. The StockMarks rating system is based on proven investment principles and is designed to drive long-term shareholder returns.